IRIS
PIERRI, IVANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.931
Totale 7.931
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.931
Totale 7.931
Salva come PNG Salva come JPEG
Città #
Genova 6.153
Rapallo 763
Genoa 650
Vado Ligure 345
Bordighera 20
Totale 7.931
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 173
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112) 169
APO866 activity in hematologic malignancies: a preclinical in vitro study. 157
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 144
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 140
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 138
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors 137
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia 136
Thalidomide in agnogenic and secondary myelofibrosis 132
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 129
Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. 128
T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. 127
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. 125
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 122
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 122
Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells 121
Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA class II antigens and in autologous mixed lymphocyte reactions. 121
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 121
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 119
Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR. 119
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 118
Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages 118
Analysis of the role of xenogeneic antigens in the proliferation of human T cells stimulated with autologous non-T cells and phytohemagglutinin-activated T cells. 115
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. 115
T-lymphocytes phenotype and functions in patients with head and neck cancer. 114
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 113
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 112
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 109
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 109
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 109
Deficiency of the autologous mixed lymphocyte reactions of non-T/T and T/T type in intravenous drug abusers infected by the human immunodeficiency virus (HIV). 109
Evidence for killing of Mesenchymal Stem Cells (MSC) by autologous natural killer lymphocytes. 107
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 107
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 106
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 105
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 104
New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting. 103
In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand 102
Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B 101
Detection of platelet-associated antibodies by flow cytometry in hematological autoimmune disorders. 101
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients 98
Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin’s lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation 97
Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans. 97
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. 97
Lymphocytapheresis in the treatment of rheumatoid arthritis: clinical and immunological studies. 96
Acute tuberculous septicemia. 94
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 94
Essential Thrombocythemia: The Dermatologic Point of View 93
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates pro-apoptotic signals in chronic lymphocytic leukemia B cells 92
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. 91
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 90
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. 90
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. 90
Role of normal adherent cells in the regulation of the autologous mixed lymphocyte reactions in humans. 88
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 87
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 86
In vitro enhancement of the proliferative response of human T cells to autologous non-T cells by hydralazine. 85
PHA-T cells in systemic lupus erythematosus and in rheumatoid arthritis: abnormalities in HLA class II antigen induction and in autologous mixed lymphocyte reactions. 84
Plasmaexchange plus immunoglobulins for treatment of hypergammaglobulinaemic patients with AIDS and AIDS-related complex (ARC). 84
Human autologous mixed lymphocyte reactions (a review). 83
[Methods for studying pleiotropic drug resistance (multidrug resistance, MDR)]. 81
[Remarks on rupture of the heart in recent myocardial infarct]. 80
Expression of HLA-class II antigens and proliferative capacity in autologous mixed lymphocyte reactions of human T lymphocytes exposed in vitro to alpha-endorphin. 79
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. 79
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa 76
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells cdan be targeted with ligands to induce apoptosis 74
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 74
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. 70
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. 69
Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method. 69
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. 69
[Plasmacytoid lymphoma of the lung. Presentation of a case and review of the literature]. 65
Decreased sensitivity of T lymphocytes to normal adherent suppressor cells in patients with head and neck cancer. 63
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 63
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? 62
[Granulomatous giant-cell endometritis due to talc]. 61
Immunocompetence in lung cancer patients: analysis of serological and cellular parameters. 59
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. 58
Thiol containing antioxidant drugs and the human immune system. 58
Totale 7.982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.320
article - articoli 21.320
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.640
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.772 0 0 0 0 211 232 354 124 180 364 218 89
2020/2021500 29 50 28 38 34 48 12 45 45 65 55 51
2021/2022943 27 73 48 111 30 60 77 206 34 88 36 153
2022/2023939 109 72 16 103 166 168 5 67 155 1 71 6
2023/2024485 27 62 8 51 45 111 24 23 20 7 30 77
2024/2025354 19 106 41 78 110 0 0 0 0 0 0 0
Totale 7.982